And more. In back-to-back announcements, Eli Lilly said it will invest $200 million to expand its manufacturing site in Suzhou and will open its biotech incubator, known as Lilly Gateway Labs ...

Eli Lilly is expanding its innovation digs to Beijing ... jobs to the plant and brings Lilly’s total investment in the Suzhou site to nearly 15 billion Chinese yuan ($2.1 billion).

[Photo/Agencies] US pharmaceutical company Eli Lilly and Co recently announced a roughly $200 million expansion of its manufacturing site in Suzhou, Jiangsu province, that will enable it to ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Yet, Eli Lilly's GLP-1 medications are helping it compete with the leader. Plus, Lilly also has several other promising catalysts to consider. These are two of healthcare's biggest darlings right ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing ...